SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?


To: Knighty Tin who wrote (79795)4/17/2000 10:32:00 PM
From: valueminded  Read Replies (1) | Respond to of 132070
 
Mike:

Do you still have GZTR or did you sell when it spiked to 10.
I have been looking with increased interest at the developing scenario with the "BXM" buyout. I am amazed that BXM, GZTR and GZSP have dropped as much as they have considering the infusion of cash which is going to be injected into the newly formed corporation. If you look at the math involved, it would seem that the market is considering a price of the newly issued shares in the 20$ range. With GZTR and GZSP at .33 and .6 respectively, it would seem to be a reasonable risk/reward scenario.
Unfortunately, was my analysis when gztr and gzsp were higher and now that gztr and gzsp continue to drop, I find myself below water. I am still unable to determine why they trade at such a discount. I understand that due to the nature of the deal, it shouldnt attract arbitrage players, as the infusion of cash is strictly for the existing bxm stockholders. But all that aside, it basically becomes a fairly massive buyback of stock and results in a company which should have a very attractive p/s ratio especially for a young biotech. What are your thoughts and are you buying here?
2nd, I have unloaded virtually all my puts at this point except a few remaining diamonds. I am hesitant to re-establish on the big name techs and am leaning more towards last years ipos. You have any thoughts/recomendations in this area. thanks in advance